CTOs on the Move

ICS Connect

www.icsconnect.com

 
ICS Connect is a Frisco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Genesis HealthCare System

Genesis HealthCare System was created in 1997 as an affiliation between Bethesda Care System and Good Samaritan Medical Center — two health care organizations that had served the community for more than 100 years each. We are a not-for-profit organization that operates two hospital sites — Genesis-Bethesda and Genesis-Good Samaritan — in Zanesville, Ohio, and several affiliated health care organizations. By combining the resources of the two organizations, we have been able to provide several new services for the community, including open-heart surgery, a Level II neonatal intermediate care unit and enhanced cancer services. Our primary service area is a six-county region of southeastern Ohio, including Muskingum, Morgan, Perry, Coshocton, Noble and Guernsey counties.

Visterra, Inc.

Visterra is a biotechnology company that uses its Atomic Interaction Network analysis to identify unique disease targets and design effective therapeutics. Our Current Business Focus on Infectious Disease Our proprietary technology is particularly well-suited to address diseases where the target is highly polymorphic and/or has frequent mutations. This has led Visterra to initially focus on infectious diseases, an area characterized by organisms with complex and evolving properties, including many different forms (polymorphism) and the potential to mutate over time. The ability of infectious organisms to avoid host immunological responses or evade treatment by current therapies has resulted in therapeutic challenges to date. Visterra's technology offers a new approach to the well-established pharmaceutical market for infectious diseases, with the ability to identify new targets and engineer novel antibodies to be broadly effective in combating these complex diseases with growing global unmet medical needs. Our Proprietary Hierotope™ Platform Visterra's technology is based on our proprietary Hierotope™ Platform, which uniquely identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function. This ideal epitope—or hierotope—becomes the target to which Visterra designs a novel therapeutic. Visterra's technology is powered by Atomic Interaction Network (AIN) analysis, which are computational tools and techniques.For protein and glycoprotein targets, our Hierotope™ Platform is able to identify the region of the protein, or epitope, which is structurally "constrained," and thus prevented from mutation over time or under immunological or therapeutic pressure. This conserved and constrained epitope, or hierotope, becomes an ideal target against which we design a novel therapeutic to effectively and durably combat the disease. For glycan targets, our Hierotope™ Platform is able to identify structural and conformational constraints of the intended target, against which we then design a novel therapeutic to effectively and durably combat the disease. Our Pipeline Visterra's lead candidate, VIS410, will enter the clinic in 2014. It is a human monoclonal antibody designed to offer truly broad-spectrum, preventive and therapeutic coverage of influenza A, neutralizing all key potential seasonal and pandemic influenza A strains, including existing strains (H1N1, H3N2) and emerging threats (H5N1, H7N9). Visterra also has a drug development program for an antibody to treat all four strains of dengue virus and expects to have its dengue antibody candidate enter the clinic in 2015. In addition, Visterra has exciting research programs focused on difficult-to-treat infectious and non-infectious diseases. Our Heritage and Investors Visterra was founded based on the scientific work of Dr. Ram Sasisekharan's research at the Massachusetts Institute of Technology. The company is backed by Polaris Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation, Omega Funds, and Alexandria Venture Investments.

sbifinechemicals

sbifinechemicals is a EDMONTON, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longmont United Hospital

At Longmont United Hospital we are committed to providing compassionate health care in a healing environment and to providing leadership to improve the health of the community we serve. We are a full-service, 201-bed, non-profit hospital. Our specialty areas include Women’s Services, Orthopedics, Cardiology, Oncology, Robotic Surgery, Transitional Care and Acute Medical Services. Our 24-hour Emergency Department is a Level III Trauma Center. Longmont United Hospital is a Planetree Patient-Centered Care Designated hospital in Northern Colorado. We have served the people of Longmont, CO for over 59 years.

Gillette Children's Specialty Health

Gillette Children's Specialty Health is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Gillette Children's Specialty Health is based in Saint Paul, MN. You can find more information on Gillette Children's Specialty Health at www.gillettechildrens.com